Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Long-Term Clinical Benefit to Anti-CCR4 Mogamulizumab: Results from the Phase 3 Mavoric Study in Previously Treated Cutaneous T-Cell Lymphoma (CTCL) Bagot, M., Dalle, S., Sokol, L., Tsianakas, A., Musiek, A., Ortiz-Romero, P., Poligone, B., Duvic, M., Elmets, C., Leoni, M., Dwyer, K., Sun, W., Nikonova, E., Kim, Y. H. AMER SOC HEMATOLOGY. 2018
View details for DOI 10.1182/blood-2018-99-118473
View details for Web of Science ID 000454842800098